These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33004811)

  • 1. Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of bla
    Hubbard ATM; Mason J; Roberts P; Parry CM; Corless C; van Aartsen J; Howard A; Bulgasim I; Fraser AJ; Adams ER; Roberts AP; Edwards T
    Nat Commun; 2020 Oct; 11(1):4915. PubMed ID: 33004811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to piperacillin/tazobactam in Escherichia coli resulting from extensive IS26-associated gene amplification of blaTEM-1.
    Hansen KH; Andreasen MR; Pedersen MS; Westh H; Jelsbak L; Schønning K
    J Antimicrob Chemother; 2019 Nov; 74(11):3179-3183. PubMed ID: 31411684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.
    Schechter LM; Creely DP; Garner CD; Shortridge D; Nguyen H; Chen L; Hanson BM; Sodergren E; Weinstock GM; Dunne WM; van Belkum A; Leopold SR
    mBio; 2018 Apr; 9(2):. PubMed ID: 29691340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of β-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli.
    Suzuki Y; Sato T; Fukushima Y; Nakajima C; Suzuki Y; Takahashi S; Yokota SI
    Int J Antimicrob Agents; 2020 Apr; 55(4):105919. PubMed ID: 32062000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in
    Yang F; Zhao Q; Wang L; Wu J; Jiang L; Sheng L; Zhang L; Xue Z; Yi M
    Pol J Microbiol; 2022 Jun; 71(2):251-256. PubMed ID: 35716168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.
    Hertz FB; Andreasen MR; Almind SR; Nielsen KL; Hansen KH; Jelsbak L; Frimodt-Møller N; Schønning K
    Int J Antimicrob Agents; 2022 Apr; 59(4):106543. PubMed ID: 35134504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli.
    Rodríguez-Villodres Á; Gutiérrez Linares A; Gálvez-Benitez L; Pachón J; Lepe JA; Smani Y
    Microbiol Spectr; 2021 Oct; 9(2):e0080121. PubMed ID: 34668721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance.
    Abdelraouf K; Chavda KD; Satlin MJ; Jenkins SG; Kreiswirth BN; Nicolau DP
    Int J Antimicrob Agents; 2020 Mar; 55(3):105885. PubMed ID: 31923568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-spectrum resistance to β-lactams/β-lactamase inhibitors (ESRI) evolved from low-level resistant Escherichia coli.
    Rodríguez-Villodres Á; Gil-Marqués ML; Álvarez-Marín R; Bonnin RA; Pachón-Ibáñez ME; Aguilar-Guisado M; Naas T; Aznar J; Pachón J; Lepe JA; Smani Y
    J Antimicrob Chemother; 2020 Jan; 75(1):77-85. PubMed ID: 31613964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
    Horiyama T; Kanazawa S; Hara T; Izawa M; Sato T; Yamaguchi T; Tsuji M; Maki H
    J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible
    Han MS; Park KS; Jeon JH; Lee JK; Lee JH; Choi EH; Lee SH
    Microb Drug Resist; 2020 Apr; 26(4):334-340. PubMed ID: 31651221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of bla
    Gálvez-Benítez L; de la Rosa JMO; Rodriguez-Villodres A; Casimiro-Soriguer CS; Molina-Panadero I; Alvarez-Marin R; Bonnin RA; Naas T; Pachón J; Cisneros JM; Lepe JA; Smani Y
    J Infect; 2023 Sep; 87(3):220-229. PubMed ID: 37442373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperacillin/tazobactam-resistant, cephalosporin-susceptible
    Edwards T; Heinz E; van Aartsen J; Howard A; Roberts P; Corless C; Fraser AJ; Williams CT; Bulgasim I; Cuevas LE; Parry CM; Roberts AP; Adams ER; Mason J; Hubbard ATM
    Microb Genom; 2022 Apr; 8(4):. PubMed ID: 35404783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
    Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.
    Rodríguez-Villodres Á; Ortiz de la Rosa JM; Álvarez-Marín R; Pachón J; Aznar J; Lepe JA; Smani Y
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061749
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity of ceftolozane-tazobactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status.
    Johnston BD; Thuras P; Johnson JR
    PLoS One; 2018; 13(7):e0200442. PubMed ID: 29990385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
    Lee J; Oh CE; Choi EH; Lee HJ
    Int J Infect Dis; 2013 Aug; 17(8):e638-43. PubMed ID: 23523562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
    Hernández-García M; García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Costa E; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Pássaro L; Paixão L; Romano J; Cantón R;
    Int J Antimicrob Agents; 2021 Feb; 57(2):106259. PubMed ID: 33310115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model.
    Islam K; Sime FB; Wallis SC; Bauer MJ; Naicker S; Won H; Zowawi HM; Choudhury MA; Shirin T; Habib ZH; Harris PNA; Flora MS; Roberts JA
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0016222. PubMed ID: 35924928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic evaluation of piperacillin/tazobactam against extended-spectrum β-lactamase (ESBL)-producing versus non-ESBL-producing Escherichia coli in a hollow-fibre infection model.
    Islam K; Sime FB; Bauer MJ; Forde BM; Wallis SC; Harris P; Naicker S; Shirin T; Habib ZH; Flora MS; Roberts JA
    Int J Antimicrob Agents; 2022 Aug; 60(2):106623. PubMed ID: 35728714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.